Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vertex Pharmaceuticals, Inc shares valued at $76,021 were purchased by LR 2019 Benefit Trust on May 21 ’25. At $447.18 per share, LR 2019 Benefit Trust acquired 170 shares.
Also, SR 2019 Benefit Trust purchased 170 shares, netting a total of over 76,021 in proceeds.
Before that, ALTSHULER DAVID had sold 52 shares from its account. In a trade valued at $22,084, the EVP, Chief Scientific Officer traded Vertex Pharmaceuticals, Inc shares for $424.69 each. Upon closing the transaction, the insider’s holdings decreased to 52 shares, worth approximately $10.71 million.
As published in a research note from Wolfe Research on May 07, 2025, Vertex Pharmaceuticals, Inc [VRTX] has been rated down from an Outperform to a Peer perform. Analysts at Leerink Partners downgraded the stock from ‘”an Outperform”‘ to ‘”a Market perform”‘ outlook in a report released in early May. Earlier on February 12, 2025, Canaccord Genuity upgraded its rating. Their new recommendation was “a Hold” for VRTX stock which previously was a “a Sell”.
Analyzing VRTX Stock Performance
On last trading session,, Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] rose 1.68% to $460.06. The stock’s lowest price that day was $451.94, but it reached a high of $460.06 in the same session. During the last five days, there has been a surge of approximately 3.66%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have jumped approximately 14.24%.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
RSI (Relative Strength Index) is 56.09 on the 14-day chart, showing neutral technical sentiment.
Is Vertex Pharmaceuticals, Inc subject to short interest?
Stocks of Vertex Pharmaceuticals, Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.63 million shares to 4.41 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 3.78 million shares. A jump of 14.25% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.07 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.07.
Which companies own the most shares of Vertex Pharmaceuticals, Inc (VRTX)?
In terms of Vertex Pharmaceuticals, Inc share price expectations, FactSet research, analysts set an average price target of 458 in the next 12 months, up nearly 1.23% from the previous closing price of $452.44. Analysts anticipate Vertex Pharmaceuticals, Inc stock to reach 545 by 2025, with the lowest price target being 400. In spite of this, 16 analysts ranked Vertex Pharmaceuticals, Inc stock as Buy at the end of 2025.
